Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 3/20 | 0.50 |
| ▸ | TUBB | P07437 | 3/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.50 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.50 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.50 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.50 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.50 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.50 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.50 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.50 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.50 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.50 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.50 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TOP1 | P11387 | 3/20 | 0.46 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8830632 | 0.89 | TOP1 (0.57) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9887734 | 0.89 | TSHR (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1928259 | 0.85 | LMNA (0.62) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL219096 | 0.84 | TUBB4A (0.55) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL28275397 | 0.84 | TUBB4A (0.55) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL668055 | 0.83 | TSHR (0.64) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL23467799 | 0.81 | TUBB1 (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10926373 | 0.81 | ABCB11 (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1808274 | 0.79 | TSHR (0.63) | TSHRTOP1TNFSF11TPMTALDH1A1 | |
| SCHEMBL16902988 | 0.79 | HTT (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368032-B | Phenolic acid derivative compound and application thereof | 大峰LS株式会社 | 2021-06-08 | — | — | CN | disclosed |
| US-10696623-B2 | Phenolic acid derivative compound and use thereof | DAEBONG LS, LTD (KR) | 2020-06-30 | — | — | US | disclosed |
| US-20180362448-A1 | NOVEL PHENOLIC ACID DERIVATIVE COMPOUND AND USE THEREOF | DAEBONG LS, LTD (KR) | 2018-12-20 | — | — | US | disclosed |
| EP-1601642-B1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-1601642-B1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2463269-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2463269-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9359289-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359289-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359289-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | disclosed |
| EP-1601642-A4 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1601642-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078924-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| EP-0541798-B1 | NEW DIAMINE COMPOUND AND BRAIN PROTECTING AGENT CONTAINING THE SAME | KOWA CO (JP) | 1995-11-29 | — | — | EP | disclosed |
| US-5389630-A | Diamine compound and brain protecting agent containing the same | KOWA CO., LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0541798-A1 | NEW DIAMINE COMPOUND AND BRAIN PROTECTING AGENT CONTAINING THE SAME | Kowa Company Ltd. (JP) | 1993-05-19 | — | — | EP | disclosed |
| US-4271193-A | PROPHYLAXIS AND TREATMENT OF GASTRITIS | KALI-CHEMIE PHARMA GMBH (DE) | 1981-06-02 | — | — | US | disclosed |
| EP-0006458-A1 | N1-Benzoyl-N2-phenyl-1,3-diaminopropane-2-ols and their salts, process for their preparation and medicaments containing them | Kali-Chemie Pharma GmbH (DE) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696623-B2 | Phenolic acid derivative compound and use thereof | TYR, COMT, PAH | TUBB4A 3719/4885TUBB 3802/4885TUBA3C 4348/4885 |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | NR2E3, NR5A1, NR5A2 | TUBB4A 3694/4885TUBB 3549/4885TUBA3C 4409/4885 |
| US-20180362448-A1 | NOVEL PHENOLIC ACID DERIVATIVE COMPOUND AND USE THEREOF | TYR, LPO, TH | TUBB4A 3527/4885TUBB 3570/4885TUBA3C 4281/4885 |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, NR5A1, NR5A2 | TUBB4A 3694/4885TUBB 3549/4885TUBA3C 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.